GlassScriptPhysician profile
Adnan Muhammad
NPI 1942242938
$150,311.19
in general payments reported to CMS, 2019-2025
25 companies · $110K in 2025
The $110K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2021: $192 · 2022: $220 · 2023: $2,422 · 2024: $37K · 2025: $110K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $127K · Travel and Lodging: $8,453 · Honoraria: $6,345 · Food and Beverage: $4,512 · Consulting Fee: $2,858 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $127,277.63 |
| Travel and Lodging | $8,452.88 |
| Honoraria | $6,345.00 |
| Food and Beverage | $4,512.02 |
| Consulting Fee | $2,857.50 |
| Education | $122.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $87,780.32 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $58,364.87 | 2025 | Wegovy |
| Echosens North America, INC. | $1,800.00 | 2023 | Fibroscan |
| Gilead Sciences, INC. | $643.81 | 2019-2025 | |
| Abbvie INC. | $637.03 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.57 | 2021-2025 | Xifaxan |
| Janssen Biotech, INC. | $168.39 | 2023 | Stelara, Remicade, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $120.81 | 2022-2025 | Entyvio, Eohilia |
| Biocompatibles, INC. | $97.46 | 2019 | |
| Mallinckrodt Hospital Products INC. | $66.51 | 2024 | Terlivaz |
| Braintree Laboratories, INC. | $59.75 | 2021-2023 | Sutab |
| Dynavax Technologies Corporation | $46.71 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $44.76 | 2023-2024 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $34.99 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $32.22 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $31.34 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.19 | 2023 | |
| Celltrion USA INC. | $25.67 | 2024 | Zymfentra |
| Genzyme Corporation | $24.90 | 2025 | |
| Vivus LLC | $20.61 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.98 | 2023 | Andexxa |
| Intercept Pharmaceuticals, INC. | $18.77 | 2023 | Ocaliva |
| Dova Pharmaceuticals | $18.53 | 2019 | |
| Shield Therapeutics INC | $17.28 | 2023 | Accrufer |
| Medtronic, INC. | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adnan Muhammad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.